HRP20020989B1 - Enantiomer 1,2-aneliranog kinolina koji inhibira farnezil transferazu - Google Patents

Enantiomer 1,2-aneliranog kinolina koji inhibira farnezil transferazu

Info

Publication number
HRP20020989B1
HRP20020989B1 HR20020989A HRP20020989A HRP20020989B1 HR P20020989 B1 HRP20020989 B1 HR P20020989B1 HR 20020989 A HR20020989 A HR 20020989A HR P20020989 A HRP20020989 A HR P20020989A HR P20020989 B1 HRP20020989 B1 HR P20020989B1
Authority
HR
Croatia
Prior art keywords
transferazu
kinolina
inhibira
farnezil
aneliranog
Prior art date
Application number
HR20020989A
Other languages
English (en)
Croatian (hr)
Inventor
Gaston Venet Marc
Rene Angibaud Patrick
William End David
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20020989A2 publication Critical patent/HRP20020989A2/hr
Publication of HRP20020989B1 publication Critical patent/HRP20020989B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20020989A 2000-06-22 2001-06-13 Enantiomer 1,2-aneliranog kinolina koji inhibira farnezil transferazu HRP20020989B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (2)

Publication Number Publication Date
HRP20020989A2 HRP20020989A2 (en) 2005-02-28
HRP20020989B1 true HRP20020989B1 (hr) 2011-05-31

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020989A HRP20020989B1 (hr) 2000-06-22 2001-06-13 Enantiomer 1,2-aneliranog kinolina koji inhibira farnezil transferazu

Country Status (33)

Country Link
US (3) US20030114471A1 (cg-RX-API-DMAC7.html)
EP (1) EP1296984B1 (cg-RX-API-DMAC7.html)
JP (1) JP4919575B2 (cg-RX-API-DMAC7.html)
KR (2) KR100846370B1 (cg-RX-API-DMAC7.html)
CN (1) CN1207296C (cg-RX-API-DMAC7.html)
AR (1) AR030704A1 (cg-RX-API-DMAC7.html)
AT (1) ATE294804T1 (cg-RX-API-DMAC7.html)
AU (3) AU2001263962B2 (cg-RX-API-DMAC7.html)
BG (1) BG65894B1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0111743B8 (cg-RX-API-DMAC7.html)
CA (1) CA2410232C (cg-RX-API-DMAC7.html)
CZ (1) CZ295278B6 (cg-RX-API-DMAC7.html)
DE (1) DE60110592T2 (cg-RX-API-DMAC7.html)
EA (1) EA005065B1 (cg-RX-API-DMAC7.html)
EE (1) EE04966B1 (cg-RX-API-DMAC7.html)
EG (1) EG24180A (cg-RX-API-DMAC7.html)
ES (1) ES2241830T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20020989B1 (cg-RX-API-DMAC7.html)
HU (1) HU229095B1 (cg-RX-API-DMAC7.html)
IL (2) IL153560A0 (cg-RX-API-DMAC7.html)
IS (1) IS2596B (cg-RX-API-DMAC7.html)
JO (1) JO2361B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02012845A (cg-RX-API-DMAC7.html)
MY (1) MY127734A (cg-RX-API-DMAC7.html)
NO (1) NO324494B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ522481A (cg-RX-API-DMAC7.html)
PA (1) PA8519501A1 (cg-RX-API-DMAC7.html)
PL (1) PL209521B1 (cg-RX-API-DMAC7.html)
SA (1) SA01220349B1 (cg-RX-API-DMAC7.html)
SK (1) SK285699B6 (cg-RX-API-DMAC7.html)
UA (1) UA73572C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001098302A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200210305B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
AU2003229688B2 (en) 2002-04-15 2009-07-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US20180338993A1 (en) * 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102514971B1 (ko) 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
EP3277842B9 (en) 2015-08-17 2020-01-15 Kura Oncology, Inc. Methods of treating cancer patients with farnesyl transferase inhibitors
PT3534885T (pt) 2016-11-03 2021-04-13 Kura Oncology Inc Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021701A1 (en) * 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO1998049157A1 (en) * 1997-04-25 1998-11-05 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
WO2000039082A2 (en) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
PT988038E (pt) 1997-06-02 2002-12-31 Janssen Pharmaceutica Nv Derivados (imidazol-5-il)metil-2-quinolinona como inibidores da proliferacao de celulas dos musculos lisos
JP4530537B2 (ja) * 1998-07-06 2010-08-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インビボ放射線増感特性をもつファルネシルタンパク質トランスフェラーゼ阻害剤
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
WO2000012499A1 (en) * 1998-08-27 2000-03-09 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
EE200100425A (et) * 1999-02-11 2002-12-16 Pfizer Products Inc. Heteroarüül-asendatud kinoliin-2-ooni derivaadid kui vähivastased vahendid
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ES2293972T3 (es) 2000-02-24 2008-04-01 Janssen Pharmaceutica N.V. Regimen de dosificacion que comprende un inhibidor de la farnesil proteina transferasa para el tratamiento del cancer.
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
AU2001293835A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021701A1 (en) * 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO1998049157A1 (en) * 1997-04-25 1998-11-05 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
WO2000039082A2 (en) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives

Also Published As

Publication number Publication date
US20030114471A1 (en) 2003-06-19
EP1296984A1 (en) 2003-04-02
HUP0300872A3 (en) 2004-11-29
SK502003A3 (en) 2003-05-02
HU229095B1 (en) 2013-07-29
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
CN1207296C (zh) 2005-06-22
EA200300048A1 (ru) 2003-04-24
NO20026032L (no) 2002-12-16
JP4919575B2 (ja) 2012-04-18
EE04966B1 (et) 2008-02-15
MY127734A (en) 2006-12-29
IL153560A (en) 2011-06-30
ES2241830T3 (es) 2005-11-01
US20070259902A1 (en) 2007-11-08
WO2001098302A1 (en) 2001-12-27
JO2361B1 (en) 2006-12-12
CZ2003114A3 (cs) 2003-05-14
CZ295278B6 (cs) 2005-06-15
US8318753B2 (en) 2012-11-27
PA8519501A1 (es) 2002-08-29
CN1437601A (zh) 2003-08-20
HRP20020989A2 (en) 2005-02-28
NO20026032D0 (no) 2002-12-16
KR20030009463A (ko) 2003-01-29
EA005065B1 (ru) 2004-10-28
NO324494B1 (no) 2007-10-29
UA73572C2 (en) 2005-08-15
KR100846370B1 (ko) 2008-07-15
AU2006220405B2 (en) 2009-05-21
ATE294804T1 (de) 2005-05-15
CA2410232A1 (en) 2001-12-27
NZ522481A (en) 2004-09-24
US8329714B2 (en) 2012-12-11
US20080114009A1 (en) 2008-05-15
BG65894B1 (bg) 2010-04-30
AU2006220405A1 (en) 2006-10-12
SK285699B6 (sk) 2007-06-07
SA01220349B1 (ar) 2007-01-23
HK1058363A1 (en) 2004-05-14
KR20070121847A (ko) 2007-12-27
IS6590A (is) 2002-10-25
AU6396201A (en) 2002-01-02
AU2001263962B2 (en) 2006-07-20
CA2410232C (en) 2008-10-07
BR0111743A (pt) 2003-07-08
DE60110592T2 (de) 2006-01-19
MXPA02012845A (es) 2003-05-15
PL209521B1 (pl) 2011-09-30
EG24180A (en) 2008-09-28
HUP0300872A2 (hu) 2003-07-28
ZA200210305B (en) 2004-03-19
PL358918A1 (en) 2004-08-23
BRPI0111743B1 (pt) 2019-03-26
IS2596B (is) 2010-03-15
BRPI0111743B8 (pt) 2021-05-25
KR100831940B1 (ko) 2008-05-23
EE200200695A (et) 2004-06-15
AR030704A1 (es) 2003-09-03
BG107310A (bg) 2003-07-31
IL153560A0 (en) 2003-07-06
EP1296984B1 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
PL335575A1 (en) Hydrophilic two-component systems for use in administration of cyclosporine
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
CA2481848A1 (en) Active ingredient particles carrying clopidogrel or a salt thereof, their use and method of preparation
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
WO2002030467A3 (en) Pharmaceutical composition containing honey for the treatment of wounds
HRP20020989B1 (hr) Enantiomer 1,2-aneliranog kinolina koji inhibira farnezil transferazu
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
JP2002542281A5 (cg-RX-API-DMAC7.html)
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
WO2001085095A3 (en) Chiral fluoroquinolizinone arginine salt forms
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
SE0001916D0 (sv) Novel formulation
WO2002004012A8 (en) Anhydrous pharmaceutical composition of vancomycin for topical use
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
JP2002501021A5 (cg-RX-API-DMAC7.html)
PL350413A1 (en) Pharmaceutical effervescent formulation containing metamizol

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190515

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200603

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20210613